Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nathan Mulure"'
Autor:
Christian Lengeler, Nathan Mulure, Said King'eng'ena, Abdunoor M. Kabanywanyi, Raymond G. Schlienger, Blaise Genton, Prudensiana Kasim
Publikováno v:
Malaria Journal, Vol 9, Iss 1, p 48 (2010)
Malaria Journal
Malaria Journal
Background Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability. Materials and methods A prospective st
Autor:
Aldo Morrone, Alem Desta, Asefaw Getachew, Andrea Bosman, Nathan Mulure, Anne-Claire Marrast, Yohannes Ambachew, Gebre Ab Barnabas, Angela Bianchi, Peter Byass, Hailemariam Lemma, Gianfranco Costanzo, Luigi Toma, Edward Fottrell
Publikováno v:
Tropical medicineinternational health : TMIH. 15(2)
To assess the impact and feasibility of artemether-lumefantrine deployment at community level, combined with phased introduction of rapid diagnostic tests (RDTs), on malaria transmission, morbidity, and mortality and health service use in a remote ar
Autor:
Aggrey Malila, Christian Lengeler, Blaise Genton, Raymond G. Schlienger, Abdunoor M. Kabanywanyi, Nathan Mulure, Christopher Migoha
Publikováno v:
Malaria Journal
Malaria Journal, Vol 9, Iss 1, p 205 (2010)
Malaria Journal, Vol 9, Iss Suppl 2, p P24 (2010)
Malaria Journal, Vol 9, Iss 1, p 205 (2010)
Malaria Journal, Vol 9, Iss Suppl 2, p P24 (2010)
Objectives To identify and implement strategies that help meet safety monitoring requirements in the context of an observational study for artemether-lumefantrine (AL) administered as first-line treatment for uncomplicated malaria in rural Tanzania.
Autor:
Nathan Mulure, Bernhards Ogutu, Obiyo Nwaiwu, Issaka Sagara, Catherine O. Falade, Salim Abdulla, Gilbert Kokwaro, Alice Ndong, Zulfiqarali Premji
Publikováno v:
Malaria Journal
Malaria Journal, Vol 7, Iss 1, p 244 (2008)
Malaria Journal, Vol 7, Iss 1, p 244 (2008)
A fixed-dose combination of artemether-lumefantrine (AL, Coartem®) has shown high efficacy, good tolerability and cost-effectiveness in adults and children with uncomplicated malaria caused by Plasmodium falciparum. Lumefantrine bioavailability is e